Silvercrest Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-8,831
Closed -$449K 873
2025
Q4
$449K Sell
8,831
-105,194
-92% -$5.38M ﹤0.01% 732
2025
Q3
$6.33M Sell
114,025
-99,345
-47% -$5.82M 0.04% 398
2025
Q2
$14.7M Sell
213,370
-8,048
-4% -$547K 0.1% 250
2025
Q1
$15.4M Buy
221,418
+93,420
+73% +$7.72M 0.11% 226
2024
Q4
$11M Buy
127,998
+3,881
+3% +$420K 0.07% 280
2024
Q3
$14.8M Buy
124,117
+5,247
+4% +$700K 0.1% 217
2024
Q2
$17M Sell
118,870
-15,190
-11% -$2.01M 0.12% 195
2024
Q1
$17.2M Buy
134,060
+11,020
+9% +$1.31M 0.12% 191
2023
Q4
$12.7M Buy
123,040
+17,733
+17% +$1.75M 0.09% 218
2023
Q3
$9.58M Sell
105,307
-5,673
-5% -$500K 0.07% 238
2023
Q2
$8.98M Sell
110,980
-8,840
-7% -$722K 0.06% 253
2023
Q1
$9.53M Sell
119,820
-31,776
-21% -$2.25M 0.07% 236
2022
Q4
$10.3M Buy
151,596
+32,166
+27% +$1.89M 0.08% 220
2022
Q3
$5.95M Sell
119,430
-4,854
-4% -$260K 0.05% 300
2022
Q2
$6.92M Buy
124,284
+13,284
+12% +$737K 0.05% 279
2022
Q1
$6.16M Buy
111,000
+446
+0.4% +$22.9K 0.04% 342
2021
Q4
$6.19M Buy
110,554
+42,428
+62% +$2.3M 0.04% 346
2021
Q3
$3.27M Buy
68,126
+15,080
+28% +$729K 0.02% 436
2021
Q2
$2.22M Sell
53,046
-330
-0.6% -$12.8K 0.01% 489
2021
Q1
$1.8M Sell
53,376
-1,660
-3% -$59.1K 0.01% 504
2020
Q4
$1.92M Buy
55,036
+2,574
+5% +$89K 0.01% 476
2020
Q3
$1.82M Buy
52,462
+2,208
+4% +$73.6K 0.02% 466
2020
Q2
$1.65M Buy
50,254
+1,504
+3% +$48K 0.01% 476
2020
Q1
$1.47M Sell
48,750
-168
-0.3% -$5K 0.02% 460
2019
Q4
$1.42M Sell
48,918
-310
-0.6% -$8.58K 0.01% 506
2019
Q3
$1.27M Buy
49,228
+390
+0.8% +$9.86K 0.01% 517
2019
Q2
$1.25M Buy
48,838
+476
+1% +$11.8K 0.01% 366
2019
Q1
$1.26M Sell
48,362
-59,308
-55% -$1.46M 0.01% 360
2018
Q4
$2.48M Buy
107,670
+480
+0.4% +$10.7K 0.03% 285
2018
Q3
$2.53M Sell
107,190
-21,832
-17% -$533K 0.02% 300
2018
Q2
$2.98M Buy
129,022
+2,524
+2% +$60K 0.03% 286
2018
Q1
$3.12M Buy
126,498
+4,630
+4% +$122K 0.03% 283
2017
Q4
$3.27M Buy
121,868
+3,550
+3% +$90.3K 0.03% 271
2017
Q3
$2.85M Buy
118,318
+386
+0.3% +$8.72K 0.03% 277
2017
Q2
$2.53M Buy
117,932
+11,430
+11% +$231K 0.03% 283
2017
Q1
$1.82M Buy
106,502
+1,930
+2% +$33.6K 0.02% 307
2016
Q4
$1.88M Sell
104,572
-18,450
-15% -$334K 0.02% 297
2016
Q3
$2.56M Buy
123,022
+4,418
+4% +$110K 0.03% 275
2016
Q2
$3.19M Buy
118,604
+20
+0% +$548 0.04% 254
2016
Q1
$3.21M Sell
118,584
-5,320
-4% -$143K 0.04% 245
2015
Q4
$3.6M Sell
123,904
-3,960
-3% -$110K 0.05% 233
2015
Q3
$3.47M Sell
127,864
-75,950
-37% -$2.15M 0.05% 220
2015
Q2
$5.58M Buy
203,814
+11,344
+6% +$319K 0.07% 205
2015
Q1
$5.14M Sell
192,470
-31,460
-14% -$724K 0.07% 201
2014
Q4
$4.74M Buy
223,930
+1,090
+0.5% +$24.3K 0.07% 203
2014
Q3
$5.31M Buy
222,840
+7,560
+4% +$174K 0.08% 198
2014
Q2
$4.97M Buy
215,280
+2,000
+0.9% +$44.2K 0.07% 203
2014
Q1
$4.87M Buy
213,280
+2,750
+1% +$58.6K 0.08% 190
2013
Q4
$3.89M Buy
210,530
+27,380
+15% +$477K 0.06% 207
2013
Q3
$3.1M Buy
183,150
+15,200
+9% +$256K 0.06% 217
2013
Q2
$2.6M Buy
+167,950
New +$2.8M 0.05% 220

Other funds holding NVO

Silvercrest Asset Management's NVO Position: Q1 2026 in Review

Silvercrest Asset Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 8,831 shares — an estimated $449K sold.

Silvercrest Asset Management first reported a position in NVO in Q2 2013 and held it in 51 quarters. The position peaked at $17.2M in Q1 2024. 1,277 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Silvercrest Asset Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Silvercrest Asset Management sold 8,831 Novo Nordisk shares in Q1 2026, an estimated $449K.
  • Silvercrest Asset Management first reported a position in Novo Nordisk in Q2 2013 and held it in 51 quarters.
  • Silvercrest Asset Management's Novo Nordisk position peaked at $17.2M in Q1 2024.
  • 1,277 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.